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Cutaneous wound healing is a highly complex biological process. The main goal of wound healing is to 
re-establish skin homeostasis and integrity and the “multi-level” cutaneous barrier functions (e.g. 
physico-chemical, immunological, biological). The physiological, regenerative-rejuvenating wound 
healing procedure contains mainly four major phases: the inflammatory, the proliferative, the granulation 
tissue formation and the tissue remodeling stages (1,s1). Traditional models for wound healing mainly 
emphasized the “almost exclusive” roles of inflammatory skin cells in skin repair. However, recent 
models (such as e.g. the ‘seed versus soil’ and ‘‘dynamic reciprocity’ ones) more comprehensively 
review the process, and propose that proper wound healing is not possible without the multi-directional 
communication of multiple skin cell populations and their interactions with a plethora of components of 
the extracellular environment (including e.g. matrix elements, intercellular communication mediators, 
cytokines, oxygen tension, mechanical shear forces, etc.) (2-3, s2-3). It can be proposed, therefore, that 
physiological skin repair involves practically all cellular and humoral elements of skin homeostasis. 
 
In a recently published issue of Experimental Dermatology, Mangoni et al contribute to our 
understanding of the skin repair process by providing an excellent, comprehensive and up-to-date 
review on the roles of antimicrobial peptides (AMPs) as endogenous mediators of skin wound healing 
(4). Originally, AMPs (among which over two thousands were described in various species) were 
introduced as part of the innate immune system and members of the host-defense arsenal of the 
organism. As such, they play “unnoticeable housekeeping” roles to control unwanted microbial 
proliferation at epithelial surfaces (s4-5).  
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Indeed, in human skin, several epithelial cell types (epidermal keratinocytes, sebaceous and eccrine 
sweat gland cells) constitutively produce multiple AMPs (e.g. RNases, psoriasin, β-defensins [hBDs], 
dermcidin, LL-37) which collectively control microbial growth (s6-7). Moreover, upon cutaneous 
inflammation/infection, AMPs can be strongly induced, either directly by invading microbes and their 
released products or by co-upregulated cytokines and growth factors. Interestingly, induction of AMPs 
takes place preferentially in the more outwards located epidermal layers whereas cytokine induction 
tends to occur primarily in the lower parts of the epidermis (5-6). This may facilitate the rapid encounter 
of invading microbes with AMPs. 
 
In addition to their direct antimicrobial properties, AMPs exhibit diverse immunomodulatory functions 
(e.g. chemotactic activity, cytokine induction, induction of cell differentiation and proliferation as well as 
putative involvement in several skin diseases), making them important and versatile players in host 
defense (7-8, s8-9). Thus, it is not surprising that AMPs seem to play also an important role in wound 
healing.  
 
The review of Mangoni et al (4) highlights that AMPs not only act as fist-line humoral guardians and 
“signal transducers” of the wound healing process towards certain skin cells, but can also directly 
promote skin repair mechanism. Indeed, multiple AMPs were implicated as endogenous regulators in 
one or more of the four phases of cutaneous wound healing (4). For example, hBD-3 (and, in part, hBD-
2) induces cytokine/growth factor release (inflammatory phase) and promotes growth of epidermal 
keratinocytes as well as chemo-attraction of macrophages (proliferative phase); furthermore, hBD-3 also 
is also implicated in the resolution of inflammation after termination of tissue remodeling (s10-11). 
Likewise, LL-37 not only stimulates migration/proliferation of cutaneous epithelial and mesenchymal cell 
types (proliferative phase), but also promotes neovascularization and angiogenesis (granulation tissue 
formation phase) (s12). Finally, certain AMPs can activate collagen synthesis and extracellular matrix 
remodeling, and are involved in neutralizing bacterial lipopolysaccharide (reviewed in 4). 
 
The above findings are translationally relevant: several ongoing human clinical trials are currently aiming 
at defining the therapeutic potential of AMP-based pharmaceuticals in skin wound healing. Indeed, in 
Phase III trials against chronically infected wounds, topical pexiganan (a synthetic analog of the natural 
AMP, magainin) exerted similar beneficial effect as orally applied ofloxacin; however, in contrast to the 
oral antibiotic, pexiganan did not promote the colonization of resistant bacteria on the wounds and was 
associated with fewer adverse effects (s13). Likewise, in a prospective trial involving a small number of 
patients, application of LL-37 (which is diminished in chronic wounds) also promoted wound healing in 
chronic leg ulcers (s14). 
 
The current elegant review of Mangoni et al (4) raises numerous open questions which need to be 
addressed in future studies. A few of these exciting themes are as follows: 
• It is now widely accepted that different skin regions (e.g. dry, moist, greasy) harbor markedly 
diverse communities of the commensal microbiota. Therefore, in order to better understand the 
roles of AMPs in wound healing and in skin biology in general, it should be determined whether 
“site-specific” and/or “microbiota-specific” AMP patterns exist and, if yes, what functional 
characteristics could be attributed to these differential configurations.  
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• As skin aging is accompanied by marked changes in both skin functions and skin microbiota, 
and, furthermore, wound healing rate and efficacy markedly decrease with age, it is also 
important to study the role of AMPs in cutaneous aging.  
• In relation to the above, it should also be revealed how the “forward and reverse” microbiota-
AMP signaling events contribute to the formation, integrity, and regeneration of the complex 
skin barrier, and hence wound repair. 
• Likewise, it is necessary to further assess whether the altered expression patterns of AMPs, 
identified in lesional (and non-lesional) psoriatic and atopic skin and wounds, may have a 
causative, pathognomic role in the development of these (and possibly other) dermatoses. 
• Evidently, it is also highly desired to uncover whether the wound healing-promoting actions of 
AMPs (found in either pre-clinical or clinical settings) are mainly due to their obvious anti-
microbial effects and/or to their direct effects on cellular and humoral components of the 
cutaneous wound healing machinery. 
• An alternative approach to be assessed is the strategy to facilitate wound healing by the 
application of AMP-inducers. For example, thrombocyte concentrate lysates induce the 
expression of AMPs in wounded skin. This may contribute to the reported beneficial effects of 
thrombocyte concentrate lysates for the healing of chronic and infected wounds (9). 
• Finally, to facilitate the design of optimal AMP-based pharmaceuticals, the exact mechanisms of 
action of the selected AMPs (which, as suggested by numerous in vitro studies, exhibit quite 
“promiscuous polypharmacology”) should be defined. 
 
Taken together, one can postulate that AMPs might become integral components of future dermatologic 
practice in the management of chronic (mostly infected) wounds, whose prevalence is ever-increasing 
thus constituting a major health care burden and socioeconomic challenge. Yet, as highlighted by the 
authors (4), future studies should also carefully address the potential risks of (long-term) AMP 
application, as these interventions might interfere with homeostatic innate immune defenses and the 
commensal microbiota of the human skin. 
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